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P2Y2 KOa b s t r a c t
Extracellular UDP-glucose can activate the purinergic P2Y14 receptor. The aim of the present study
was to examine the physiological importance of P2Y14 receptors in the vasculature. The data pre-
sented herein show that UDP-glucose causes contraction in mouse coronary and basilar arteries.
The EC50 values and immunohistochemistry illustrated the strongest P2Y14 receptor expression in
the basilar artery. In the presence of pertussis toxin, UDP-glucose inhibited contraction in coronary
arteries and in the basilar artery it surprisingly caused relaxation. After organ culture of the coro-
nary artery, the EC50 value decreased and an increased staining for the P2Y14 receptor was observed,
showing receptor plasticity.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Nucleotides are extracellular signal molecules that can activate
purinergic receptors in different tissues. There exist two main fam-
ilies of nucleotide-activated purinergic receptors: the P2X receptor
family of ligand-gated ion channels and the P2Y receptor family of
G-protein coupled receptors [1]. Freemann and colleagues showed
that the orphan G-protein receptor GPR105 was activated by UDP-
glucose [2]. UDP-glucose can be released by cells, and thus extra-
cellular UDP-glucose can be present [3]. All signalling components
for this receptor were present, and it was classiﬁed as a purinergic
receptor and given the name P2Y14 [4]. Later, Fricks and colleagues
showed that the intracellular pathway for the P2Y14 receptor is
coupled to the inhibitory G-protein (Gi) that inhibits the adenylyl
cyclase, thereby lowering cellular cAMP levels [5].
The P2Y14 receptor is expressed widely in the body, e.g., in
brain, heart, skeletal muscles and spleen [6]. Most of the work so
far has been done on neutrophils where UDP-glucose is a chemo
attractant [7–9]. Nucleotides have a well-established physiological
role in vascular smooth muscle cells, where the purinergic recep-
tors modulate the contraction and relaxation [10,11]. Very recently,
Alsaqati and colleagues reported that UDP-glucose elicitedvasoconstriction in porcine pancreatic arteries [12]. This study
was designed to examine the physiological importance of the
P2Y14 receptor in the vasculature, speciﬁcally in the brain (basilar
artery) and heart (left anterior descending artery). Since UDP-glu-
cose has been shown to also activate P2Y2 receptors [13], experi-
ments were performed on wild type (WT) and on P2Y2 receptor
knock out (KO) mice [14].
The A2A adenosine receptor acts through the stimulatory G-pro-
tein (Gs) and increases cellular cAMP levels leading to an endothe-
lium independent relaxation [15]. We aimed to investigate whether
the P2Y14 receptor could be involved in smoothmuscle contraction
via Gi activation and if it could be counteracted by the Gs relaxing
effect of adenosine. The experiments presented here show that
the P2Y14 receptor is indeed a contractile receptor that is expressed
in the cerebral and coronary arteries, and that the P2Y2 receptor
interference is minor. Organ culture of coronary artery segments
revealed enhanced expression of the P2Y14 receptor, demonstrat-
ing receptor plasticity.
2. Materials and methods
2.1. Myography
Mixed female andmale BalbCmice (WT or P2Y2KO [backcrossed
for 7 generations];20 g, n = 52) were sedated with 70% CO2 in 30%
O2 and killed by decapitation. Heart and brain were immediately
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ical saline solution (Ca2+-free PSS) composed of (in mM): 119 NaCl,
4.7 KCl, 2.5 CaCl2, 25NaHCO3, 1.17MgSO4, 1.18 KH2PO4, 5.5 glucose,
and0.03EDTA, pH7.4. The LAD (left anterior descending) andbasilar
artery (segments length  2 mm) were dissected in ice cold, oxy-
genated Ca2+-free PSS and mounted on a Mulvany–Halpern wire
myograph (Danish Myo Technology, Denmark). The myographs
were connected to a PowerLab Unit and responses were sampled
in LabChart™ (ADInstruments, UK). The mounted artery segments
were heated to 37 C, and buffer changed for PSSwith calcium. After
15 min equilibration, the vessels were stretched to their optimal
lumen diameter L1 = 0.9  L100, where L100 is an estimate of the
diameter of the vessel under a passive transmural pressure 6 kPa
for the basilar artery and 9 kPa for the coronary arteries, in order
to obtain optimal conditions for active tension development. Subse-
quently, the vessels were allowed to stabilize for 20–30 min. The
vessels were kept at this standard tension during the entire period
in the myograph. To ensure a stable pH and bicarbonate concentra-
tion at25 mM(pH7.40), allmyographbathswere continuouslybub-
bled with 12% CO2 in 88% O2, to compensate for the large surface to
volume ratio.
The vascular smooth muscle cell contractile function was con-
ﬁrmed by challenging the segments two times with 125 mM K+
(KPSS, similar to PSS except that NaCl was exchanged for KCl on
an equimolar basis). All contractile responses are expressed as per-
centage of the average maximal contraction induced by the K+
response, with either normal baseline or PGF2a (Prostaglandin
F2a) contraction as baseline. The vessels where pre-contracted
with 2  106 M PGF2a for coronary arteries and 3  106 M PGF2a
for cerebral arteries, producing about 50% of the contraction seen
with 105 M PGF2a. This allows for ﬁne tuning of the contractile
response, e.g. by cAMP. All concentration response curves were
made in a cumulative manner.
2.2. Endothelial inﬂuence
The addition of 105 M carbachol after precontraction by
105 M PGF2a, was used to assess the endothelial function. The
endothelium dependent carbachol effect value is expressed in %,
where 100% is a relaxation back to the baseline. The vessels used
in this study are very small; therefore inserting the myograph wire
will sometimes cause a partial or full removal of the endothelium.
Since we have a varying degree of endothelium (determined by the
carbachol induced relaxation) we can correlate the amount of func-
tional endothelium cells with an agonist induced contraction [16].
The inﬂuence of the endothelium on the Emax values of UDP-glu-
cose was analysed by constructing a correlation curve of the Emax
and the endothelium-dependent carbachol effect.
2.3. Organ culture
Mouse coronary arteries (LAD segment), with one myograph
wire inside, were incubated in DMEM media (+penicillin/strepto-
mycin, no serum) for 24 h at +37 C and 5% CO2. Segments were
subsequently either mounted in the myograph or used for immu-
nohistochemistry/Western blot.
2.4. Immunohistochemistry
Mouse coronary arteries (LAD segment) and cerebral arteries
(basilar segment), either with a surrounding tissue block or iso-
lated and incubated for 24 h, were immersed in 4% buffered form-
aldehyde solution. Tissue blocks were ﬁxed for 5 h and vessels for
2 h. The tissue was cryoprotected by incubating it in 10% sucrose in
Sorensen’s buffer phosphate buffer (0.1 M NaH2PO4 and 0.1 M Na2-HPO4) overnight, followed by 25% sucrose for 24 h. The tissue was
covered with tissue TEK (Gibco) and sectioned at a thickness of
10 lmon a cryostat (Leica Microsystems GmBH, Germany). All sec-
tions were blocked with 5% donkey serum (Jackson ImmunoRe-
search Europe, Suffolk, UK) for 30 min, and incubated with
primary antibodies directed against the P2Y14 receptor (rabbit
anti-GPR105/P2Y14, Ab136264, 1:200, Abcam, UK) in PBS contain-
ing 1% BSA and 0.25% Triton X-100, overnight. Secondary antibody
(Alexa Fluor 488, donkey anti-rabbit 1:400, Jackson ImmunoRe-
search Europe, Suffolk, UK) was added after washing with PBS-Tri-
ton X-100. Slides were mounted with Vectashield with DAPI.
Immunoreactivity was visualized and photographed with a Nikon
microscope (EZ-c1, Germany), with the following ﬁlters: DAPI
(EX340-38, DM400, BA/EM435-485) and Alexa488 (EX465-495,
DM505, BA/EM515-555).
2.5. Western blot
Dissected arteries were homogenized immediately, in boiling
SDS loading buffer (Expedeon, Kem-en-tec, Denmark), sonicated,
frozen and re-sonicated before being heated to 70 C for 10 min.
10 ll of the sample was loaded into each well on a 4–20% gradient
gel. The proteins were transferred to PVDF membranes (GE Health-
care, Denmark) using wet electroblotting. The membranes were
blocked overnight using 2% ECL™ Advance Blocking Agent (GE
Healthcare, Denmark), incubated overnight at 4 C in primary anti-
body solutions (rabbit anti-GPR105/P2Y14, Ab136264, 1:500or goat
anti-SM22 1:2,000, both from Abcam, UK), washed brieﬂy in TBS-T
(Tris buffered saline + 0.01% Tween-20) and then incubated with
secondary antibody (ECL™ donkey anti rabbit 1:20,000, or DAKO
donkey anti goat 1:2000) for 1.5 h at room temperature.Membranes
werewashed (5  5 min in TBS-T) and developed using ECL™ Select
Western Blotting Detection Kit (GE Healthcare, Denmark). Image
capture was done using a LAS-1000 digital camera unit and quanti-
ﬁcation using Multi gauge 3.2 (Fujiﬁlm, Denmark).
2.6. Chemicals, data analyses and statistics
All drugs and chemicals for myograph studies were acquired
from Sigma–Aldrich, Germany.
Data were analysed using GraphPad Prism software (GraphPad
Software Inc., USA) and expressed as mean ± SEM (n equals the
number of animals). EC50 (or as negative logarithm: pEC50) repre-
sents the agonist concentration required to produce 50% of the
maximum response, calculated using non-linear regression. Where
no clear maximum contraction was observed, the max value was
set to be 60% K+; this could lead to underestimates of the EC50 val-
ues. Paired and unpaired Student’s t-test was used to compare two
groups. Where there were three groups, one-way repeated mea-
sures ANOVA with Bonferroni Multiple Comparisons Post-hoc test
was used. To compare concentration curves, two-way ANOVA with
repeated measurements was used to determine statistical signiﬁ-
cance. All statistical analyses were considered signiﬁcant when
P < 0.05.
3. Results
3.1. UDP-glucose causes contraction in coronary and basilar artery
We ﬁrst aimed to examine if UDP-glucose could induce arterial
contraction, presumably acting through Gi [5] and counteracted by
stimulation of relaxing A2A adenosine receptors that operate
through Gs [17]. Therefore, isolated coronary and cerebral arteries
from mice were mounted in a wire myograph. The contraction
induced by 125 mM K+ was 1.26 ± 0.17 mN/mm in WT and
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Both WT and P2Y2 receptor KO arteries precontracted with
2  106 M PGF2a showed a strong contraction upon further treat-
ment with UDP-glucose (Fig. 1A). In order to determine the con-
centration-dependence of the UDP-glucose contraction, the PGF2a
contraction was used as baseline. UDP-glucose induced a concen-
tration-dependent contraction in coronary arteries with a high
EC50 value estimated to be 100 lM (pEC50 4 ± 1.42) for WT and
428 lM (pEC50 3.4 ± 5.771) for P2Y2 receptor KO, using non-linear
regression with 60% K+ considered the theoretical maximal con-
traction (Fig. 1B). The concentration-dependences observed were
similar in WT and P2Y2 receptor KO, although there was a non-sig-
niﬁcant downward shift in the P2Y2 receptor KO (Fig. 1B).
Even if the EC50 value was high, it could still be acting through
an adenylyl cyclase dependent mechanism. Indeed, when UDP-glu-
cose (1 mM) was added to arteries precontracted with PGF2a, Gs
activation by adenosine (300 lM) could only relax the arteries
down to the PGF2a baseline, which could suggest that it relaxed
the UDP-glucose-induced contraction, by counteracting the Gi
(Fig. 1C). However, we cannot rule out that adenosine reverses
the PGF2a-induced vasoconstriction without affecting the responseFig. 1. UDP-glucose-induced contraction in fresh coronary arteries. (A) Basal constrictio
WT and P2Y2 KO. ⁄P < 0.05, using paired Student’s t-test (n = 8–9). (B) UDP-glucose in
arteries from WT and P2Y2 KO mice. (C) WT arteries were precontracted with PGF2a, foll
arteries were precontracted with PGF2a and only 300 lM adenosine was added. ⁄P <
measures with Bonferroni’s Multiple Comparison Post-hoc Test (part 1), or paired Studen
(1 mM) and the % endothelial function (% relaxation induced by carbachol; see methodsto UDP-glucose. When adenosine was added to arteries only pre-
contracted with PGF2a, 300 lM adenosine induced complete relax-
ation (Fig. 1C). In order to determine if the endothelial cells have
any inﬂuence on the UDP-glucose induced contraction, endothelial
function (as per cent relaxation induced by carbachol and higher
per cent equals stronger endothelium function [16]) was plotted
versus the Emax of 1 mM UDP-glucose (Fig. 1D). There was no
apparent correlation between the endothelium dependent carba-
chol effect and the UDP-glucose-induced contraction.
In basilar arteries, 125 mM K+ caused a contraction of
0.5 ± 0.12 mN/mm inWT and 0.65 ± 0.14 mN/mm in P2Y2 receptor
KO. UDP-glucose induced an absolute smaller contraction than in
the coronary arteries, as seen for both WT and P2Y2 receptor KO
arteries (Fig. 2A). The concentration-dependence was different,
with a much lower EC50 value in both WT (97 nM, pEC50
7.0 ± 1.7) and KO (681 nM, pEC50 6.2 ± 0.4). There was no signiﬁ-
cant difference between arteries from WT or P2Y2 receptor KO
mice. However, a more sigmoidally shaped curve can be observed
in the P2Y2 receptor KO arteries, illustrating a slight interference
from UDP-glucose binding to the P2Y2 receptor (Fig. 2B). Adeno-
sine relaxed the arteries below the PGF2a baseline (Fig. 2C). Then by PGF2a and the additional Emax constriction induced by UDP-glucose (1 mM) in
duced a concentration-dependent contraction of freshly isolated mouse coronary
owed by 1 mM UDP-glucose and then 300 lM adenosine. In the second experiment,
0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, ###P < 0.001, (n = 4) with one-way ANOVA repeated
t’s t-test (part 2). (D) A comparison of the contractile effect of Emax of UDP-glucose
).
Fig. 2. UDP-glucose induced contraction in fresh coronary arteries. (A) Basal constriction by PGF2a and the additional Emax constriction induced by UDP-glucose (300 lM) in
WT and P2Y2 KO. ⁄P < 0.05, using paired Student’s t-test (n = 6–9). (B) UDP-glucose induced a concentration-dependent contraction of freshly isolated mouse basilar arteries
from WT and P2Y2 KO mice. (C) WT arteries were precontracted with PGF2a followed by 1 mM UDP-glucose and then 300 lM adenosine. In the second experiment, arteries
were precontracted with PGF2a and only 300 lM adenosine was added. ⁄P < 0.05, ⁄⁄P < 0.01, ###P < 0.001, (n = 4), with one-way ANOVA repeated measures with Bonferroni’s
Multiple Comparison Post-hoc Test (part 1), or paired Student’s t-test (part 2). (D) A comparison of the contractile effect of Emax of UDP-glucose (300 lM) and the %
endothelial function (% relaxation induced by carbachol, see methods).
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plete relaxation. The relation between endothelial cell-derived
effects of carbachol and Emax contraction induced by 300 lM UDP
glucose was determined (Fig. 2D). Most basilar arteries did not
have any endothelial function, but for those that had, there was
no apparent correlation between endothelia function and UDP-glu-
cose-induced contraction.
3.2. P2Y14 expression
To investigate the expression of the P2Y14 receptor, we per-
formed immunohistochemistry on whole heart and brain seg-
ments. The staining illustrated that the P2Y14 receptor is very
weakly expressed in the coronary artery. However, it seems to be
strongly expressed in myocytes of the heart (Fig. 3A). In the basilar
artery, the staining appeared stronger (Fig. 3B).
We also detected P2Y14 using Western blotting. Since there
was a tendency towards different concentration-dependence for
the WT and P2Y2 receptor KO arteries, we also aimed to determine
if there could be any expression differences for the P2Y14 receptor.
Fig. 4A shows a representative Western blot for P2Y14, with an
adult smooth muscle speciﬁc marker, SM22 [18], as loadingcontrol. One band at around 60 kD was observed for P2Y14, which
correlates well with the expected molecular mass of this receptor
in its glycosylated form [19]. The quantiﬁcation showed no differ-
ence in the P2Y14 receptor expression between WT and P2Y2
receptor KO arteries (Fig. 4B). Interestingly, we observed a signiﬁ-
cantly higher expression of P2Y14 in the basilar artery (Bas) com-
pared to the coronary artery (LAD), in a pooled WT/KO
quantiﬁcation (Fig. 4C).
3.3. Effect of pertussis toxin on the UDP-glucose-induced responses
Since UDP-glucose couples through the inhibitory G protein
(Gi), we decided to conﬁrm that the UDP-glucose response is med-
iated through the Gi protein in arteries. Pertussis toxin (PTX,
200 ng/ml) was incubated with theWT vessels for 30 min (an incu-
bation time previously used for arteries [20]), after which PGF2a
was added. PTX signiﬁcantly inhibited the UDP-glucose-induced
contraction in coronary arteries (Fig. 5A). Interestingly, in the bas-
ilar artery PTX not only inhibited UDP-glucose induced contraction,
but UDP-glucose instead induced relaxation of the basilar artery
(Fig. 5B). Gq coupled contraction was not affected by PTX, as ET-
1 induced contraction was 144 ± 29% in coronary arteries without
Fig. 3. Immunohistochemical detection of P2Y14 in mouse arteries. (A) Staining of the coronary artery surrounded by myocytes. (B) Staining of the basilar artery surrounded
by brain tissue; smooth muscle cells show a clear staining. Illustration is representative for three different animals. Scale bar is 50 lm.
Fig. 4. P2Y14 receptor expression in WT and P2Y2 KO. (A) Western blot performed on WT and P2Y2 KO LAD (left anterior descending) and Bas (basilar) artery tissue,
illustrating the band for P2Y14 corresponding to ca. 60 kD. (B) Quantiﬁcation of P2Y14 receptor expression in LAD and Bas (2 or 4 pooled arteries respectively, different
isolations, n = 2–3). (C) Difference in expression of the P2Y14 receptor between LAD and Bas in the pooled experiments, relative to SM22 (n = 4–6 ⁄P < 0.05, with unpaired t-
test).
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arteries, where the ET-1 contraction was 164 ± 22% without PTX
and 179 ± 11% with PTX. All numbers are expressed as % of the
125 mM K+ response, and there were no signiﬁcant differences.
3.4. Organ culture induces upregulation of P2Y14
Previous in vivo work has revealed that cerebral ischemia [21]
or coronary artery occlusion followed by reperfusion [16] results
in upregulation of cerebral or coronary artery ETB vascular smooth
muscle receptors. Organ culture of artery segments results in a
similar type of enhanced receptor expression in cerebral vessels
and coronary arteries [16,22,23]. Therefore, we hypothesized that
P2Y14 could be upregulated in this model. Indeed, we observed a
clear P2Y14 receptor upregulation in both WT and P2Y2 receptor
KO coronary arteries (Fig. 6A and B). The EC50 for the both the
WT and P2Y2 receptor KO arteries were signiﬁcantly reduced. In
WT arteries the EC50 is estimated to be 2.1 lM (pEC50 5.7 ± 1.5)
and in the P2Y2 receptor KO arteries the EC50 value is 2.8 lM
(pEC50 5.5 ± 0.65) after organ culture.
Immunohistochemistry of coronary arteries showed weak
staining in the fresh artery (Fig 7A). The staining in the organ cul-
tured arteries revealed a clear positive staining in the vascular
smooth muscle cells (white arrows, Fig. 7B). Using quantitativeWestern blotting (Fig. 7C), there was an up regulation on the pro-
tein level (P = 0.043, n = 8–9).
4. Discussion
The present study has for the ﬁrst time revealed that both cor-
onary and cerebral arteries contract in response to UDP-glucose.
Since it has been reported that UDP-glucose can activate the
P2Y2 receptor [13], concentration-dependence curves for both
WT and P2Y2 receptor KO arteries were performed. This eliminated
the need for using high concentrations of the more P2Y14-speciﬁc
agonist MRS2690. There was no signiﬁcant difference between the
WT and P2Y2 receptor KO arteries (Figs. 1 and 2), and there was no
difference in P2Y14 receptor expression (Fig. 4). However, a more
sigmoidal shape of the concentrations-dependence curve in the
freshly isolated basilar artery was observed (Fig. 2B), suggesting
that UDP-glucose could partially activate P2Y2 receptors. After
organ culture the P2Y14 receptor is upregulated in the coronary
artery with similar concentration-dependence differences between
WT and P2Y2 receptor KO arteries (Fig. 6A and B) as observed in
the basilar artery (Fig. 2B). Together, this illustrates that binding
of UDP-glucose to the P2Y2 receptor causes only a small change
in the concentration-dependence of the UDP-glucose induced
contraction.
Fig. 5. The effect of pertussis toxin on coronary and basilar artery contraction. (A)
Pertussis toxin (PTX) signiﬁcantly decreased the contraction caused by UDP-glucose
in coronary arteries (n = 4, ⁄P < 0.05 with two-way ANOVA). (B) In basilar artery
incubated with PTX, UDP-glucose caused a relaxation instead of contraction (n = 4;
⁄P < 0.05 with two-way ANOVA).
Fig. 6. P2Y14 is functionally upregulated upon organ culture. UDP-glucose-induced con
response curve compared to freshly isolated arteries (⁄P < 0.05, with two-way ANOVA) i
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surprisingly high estimated EC50 value, 100 lM in WT and
428 lM in P2Y2 receptor KO arteries (Fig. 1B); this was much
higher than those observed in other systems, with EC50 values in
transfected HEK293 cells of 323, 82, or 26 nM [2,5,24]. The concen-
tration-dependence observed in cerebral vessels, however, are
within the ﬁndings of these previous studies, with an EC50 of
97 nM inWT and 681 nM in P2Y2 receptor KO (Fig. 2B). EC50 values
are not reported for the effect of UDP-glucose in porcine arteries
[12]. However, the EC50 values seem to be similar to those
observed here in the fresh coronary arteries. The contraction
induced by UDP-glucose is smaller in the basilar artery compared
to the coronary artery (Figs. 1A and 2A), even though the expres-
sion is higher (Fig. 4). The PGF2a induced contraction is also smaller
(Figs. 1A and 2A), which could suggest that there are differences in
the intracellular pathways between the two arteries.
With the support of immunohistochemistry and Western blot
(Figs. 3 and 4), it is clear that the P2Y14 receptor is expressed in
fresh basilar artery. For the freshly isolated coronary arteries, the
staining is weak but there is a clear band in the Western blot
(Figs. 3 and 4). In addition, the P2Y14 receptor appears to be
strongly expressed in the myocytes of the heart and also in the
brain (Fig. 3); this may be a future avenue of research. In recent
work by Alsaqati and colleagues [12], a partially endothelium-
dependent UDP-glucose contraction was observed. Although the
role of the endothelium was not directly investigated in this study,
we performed a correlation analysis between the endothelium
function and the Emax of UDP-glucose (Figs. 1D and 2D). We did
not observe any clear endothelium dependence for the Emax value.
We also aimed to investigate the interplay between adenosine
and UDP-glucose. When adenosine is added after a precontraction
with both PGF2a and subsequently added UDP-glucose, it cannot
relax the arteries fully (Figs. 1C and 2C) as it can in the absence
of UDP-glucose. This suggests that the in vivo function of UDP-glu-
cose could be to counteract the relaxing effect of adenosine.
There is no commercial available inhibitor for the P2Y14 recep-
tor. Therefore, pertussis toxin was used to generally inhibit Gi pro-
teins, the transducers for the P2Y14 receptor [5]. The coronary
artery response was accordingly reduced (Fig. 5A). Therefore, it is
most likely that the UDP-glucose effect is indeed Gi coupled,
despite the high EC50. The most interesting result was the effect
of pertussis toxin in the basilar artery. Here, the toxin not only
abolished the contraction, but UDP-glucose induced a relaxationtraction in cultured coronary arteries exhibited a strong leftward shift in the dose
n the dose response in (A), WT mice (n = 6–9) and (B) P2Y2 KO mice (n = 4–8).
Fig. 7. P2Y14 protein expression is upregulated upon organ culture. (A) In fresh
coronary arteries, there is a weak staining for P2Y14. (B) After incubation for 24 h in
DMEM medium, the coronary artery shows a stronger positive staining for the
P2Y14 receptor in the smooth muscle cells (white arrows). The inserts at higher
magniﬁcation are from between the two white lines. Illustrations are representative
of three different animals and both scale bars are 25 lm. (C) Difference in P2Y14
receptor expression in fresh and 24 h-incubated coronary arteries, together with a
representative Western blot (⁄P < 0.05 with unpaired Student’s t-test).
2942 K.A. Haanes, L. Edvinsson / FEBS Letters 588 (2014) 2936–2943after PTX treatment (Fig. 5B). This is a surprising ﬁnding, and there
are two possible explanations. The ﬁrst possibility is the presence
of a second receptor for UDP-glucose that does not couple through
Gi. The most likely candidate for this relaxation would be a Gs cou-
pled receptor, similar to the A2A receptor. The second possibility is
that the P2Y14 receptor couples not only through Gi, but also
through Gs, although to a smaller degree. This has been seen for
other G-protein coupled receptors, e.g., in a P2Y13 overexpression
system [25] and has been suggested upon mathematical modelling
of Gi-inhibition/Gs-activation of adenylyl cyclase [26].
We have previously shown that endothelin receptors, in partic-
ular the ETB receptor, are upregulated in the coronary artery down-
stream of an induced heart attack, and that similar effects can be
seen after organ culture for 24 h [16,22,23]. After 24 h of incuba-
tion, we observed a clear leftward shift in the concentration–
response curve, with an estimated EC50 value of 2.1 lM for WT
and 2.8 lM for P2Y2 receptor KO (Fig. 6). This is much closer to
previously reported EC50 values (see above). This value is close to
the expected value for the P2Y14 receptor, and is more similar to
what we observed in the basilar artery (97 nM in WT and
681 nM in P2Y2 receptor KO). This decreased EC50 value is accom-
panied by the presence of a stronger positive staining for P2Y14
receptor (Fig. 7B), compared to the fresh artery (Fig. 7A). An
increase in the protein expression was also observed in a Western
blot (Fig. 7C).
In conclusion, we have demonstrated that UDP-glucose can
induce contraction through the P2Y14 receptor in both mouse cor-
onary and basilar arteries, and that the contraction is not signiﬁ-
cantly affected by the P2Y2 receptor. The EC50 values,
immunohistochemistry and Western blot, illustrate that the stron-
gest expression is in the basilar artery, where an additional UDP-
glucose receptor not coupled to Gi may be expressed, or where
the P2Y14 receptor may partially couple also to Gs. After organ cul-
ture of the coronary artery, the EC50 value matched that of the bas-
ilar artery and we observed a clear increase in the smooth muscle
staining for P2Y14 receptor.
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